Published in Biochemistry on October 29, 1996
Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol (2003) 1.16
Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood (2008) 1.03
Pathogenic role of antiphospholipid antibodies. Lupus (2008) 0.89
The insertion of human apolipoprotein H into phospholipid membranes: a monolayer study. Biochem J (1998) 0.88
Membrane binding of beta2-glycoprotein I can be described by a two-state reaction model: an atomic force microscopy and surface plasmon resonance study. Biochem J (2005) 0.87
Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. J Clin Invest (1997) 0.86
Interaction of β2-glycoprotein I with lipopolysaccharide leads to Toll-like receptor 4 (TLR4)-dependent activation of macrophages. J Biol Chem (2011) 0.85
Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids. Biochem J (1999) 0.83
A novel dimeric inhibitor targeting Beta2GPI in Beta2GPI/antibody complexes implicated in antiphospholipid syndrome. PLoS One (2010) 0.82
Membrane-induced conformational change in human apolipoprotein H. Biochem J (2000) 0.82
Studies on specific interaction of beta-2-glycoprotein I with HBsAg. World J Gastroenterol (2003) 0.81
Testing for and clinical significance of anticardiolipin antibodies. Clin Diagn Lab Immunol (1999) 0.80
Human apolipoprotein H may have various orientations when attached to lipid layer. Biophys J (2002) 0.79
Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies. Blood (2005) 0.79
Effect of Low Molecular Weight Heparins (LMWHs) on antiphospholipid Antibodies (aPL)-mediated inhibition of endometrial angiogenesis. PLoS One (2012) 0.78
Attachment of beta 2-glycoprotein I to negatively charged liposomes may prevent the release of daughter vesicles from the parent membrane. Eur Biophys J (2008) 0.77
Both kinetic data and epitope mapping provide clues for understanding the anti-coagulant effect of five murine monoclonal antibodies to human beta2-glycoprotein I. Immunology (1999) 0.76
An A1-A1 mutant with improved binding and inhibition of β2GPI/antibody complexes in antiphospholipid syndrome. FEBS J (2015) 0.76
Quantitative determination of the binding of beta2-glycoprotein I and prothrombin to phosphatidylserine-exposing blood platelets. Biochem J (2005) 0.75
Thrombomodulatory Effect of Anti-B2-Glycoprotein I Antibodies on Crystalline Annexin A5 on Phospholipid Bilayers, as Observed by Atomic Force Microscopy. EJIFCC (2011) 0.75
Anti-phospholipid antibodies (aPL) and apoptosis: prothrombin-dependent aPL as a paradigm for phospholipid-dependent interactions with apoptotic cells. Thromb Res (2004) 0.75
Biotinylation of glycan chains in beta2 glycoprotein I induces dimerization of the molecule and its detection by the human autoimmune anti-cardiolipin antibody EY2C9. Biochem J (2006) 0.75
Identification of the binding site for fondaparinux on Beta2-glycoprotein I. Biochim Biophys Acta (2013) 0.75
Ultraviolet-A1 irradiation therapy for systemic lupus erythematosus. Lupus (2017) 0.75
Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies. Br J Cancer (2017) 0.75
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet (1990) 6.54
Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost (2009) 4.95
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med (1995) 4.32
The asymmetric distribution of phospholipids in the human red cell membrane. A combined study using phospholipases and freeze-etch electron microscopy. Biochim Biophys Acta (1973) 3.83
Localization of red cell membrane constituents. Biochim Biophys Acta (1973) 2.88
Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost (2007) 2.86
Relation between various phospholipase actions on human red cell membranes and the interfacial phospholipid pressure in monolayers. Biochim Biophys Acta (1975) 2.42
The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem (1980) 2.39
Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci (2005) 2.32
The enzymatic synthesis of phosphatidylserine and purification by CM-cellulose column chromatography. Biochim Biophys Acta (1977) 2.14
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum (2012) 1.96
The adsorption of prothrombin to phosphatidylserine multilayers quantitated by ellipsometry. J Biol Chem (1983) 1.94
Lipid translocation across the plasma membrane of mammalian cells. Biochim Biophys Acta (1999) 1.93
Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta (1983) 1.74
Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost (1993) 1.65
Disseminated human herpesvirus 6 infection in AIDS. Lancet (1993) 1.64
Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat (2009) 1.62
Lipid-protein interactions in blood coagulation. Biochim Biophys Acta (1998) 1.62
Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem (1982) 1.61
Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis. Clin Exp Immunol (1985) 1.57
Membrane asymmetry and blood coagulation. Nature (1977) 1.57
Epidemiology of post-infarction risk stratification strategies in a country with a low volume of revascularization procedures. GISSI-Prognosis Investigators. Eur Heart J (1998) 1.56
Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost (1991) 1.55
Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. Biochim Biophys Acta (1986) 1.53
Organization of phospholipids in human red cell membranes as detected by the action of various purified phospholipases. Biochim Biophys Acta (1975) 1.53
Accuracy and reliability of frozen section diagnosis in a series of 672 nonpalpable breast lesions. Am J Clin Pathol (1995) 1.51
High prevalence of human T cell lymphotropic virus type II infection in patients affected by human immunodeficiency virus type 1--associated predominantly sensory polyneuropathy. J Infect Dis (1995) 1.47
Lytic and non-lytic degradation of phospholipids in mammalian erythrocytes by pure phospholipases. Biochim Biophys Acta (1973) 1.45
Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol (1996) 1.45
Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev (1994) 1.42
Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol (1993) 1.42
Plasma activity of muscle enzymes: quantification of skeletal muscle damage and relationship with metabolic variables. Int J Sports Med (1989) 1.42
Thallium-201 reverse redistribution at reinjection imaging correlated with coronary lesion, wall motion abnormality and tissue viability. J Nucl Med (1996) 1.41
Increased levels of beta 2-glycoprotein I (aca-Cofactor) in patients with lupus anticoagulant. Thromb Haemost (1992) 1.39
Beta 2-glycoprotein I for binding of anticardiolipin antibodies to cardiolipin. Lancet (1990) 1.38
Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome. Clin Exp Immunol (1986) 1.37
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS (1999) 1.36
Complete purification and some properties of phospholipase C from Bacillus cereus. Biochim Biophys Acta (1971) 1.35
Terrestrial gamma-ray flashes as powerful particle accelerators. Phys Rev Lett (2011) 1.35
Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochim Biophys Acta (1990) 1.34
Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J Biol Chem (2001) 1.34
Transbilayer movement of phospholipids in red cell and platelet membranes. Biochim Biophys Acta (1991) 1.33
Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS (1997) 1.32
Action of highly purified phospholipases on blood platelets. Evidence for an asymmetric distribution of phospholipids in the surface membrane. Biochim Biophys Acta (1977) 1.31
Topological asymmetry of phospholipid metabolism in rat erythrocyte membranes. Evidence for flip-flop of lecithin. Eur J Biochem (1976) 1.29
Use of the normalcy index for the evaluation of gait pathology. Gait Posture (2004) 1.28
Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood (1991) 1.28
Freeze-fracture appearance and disposition of band 3 protein from the human erythrocyte membrane in lipid vesicles. Eur J Biochem (1978) 1.26
The solubilization of human erythrocyte membranes by n-pentanol. Biochim Biophys Acta (1968) 1.25
Occurrence of running injuries in adults following a supervised training program. Int J Sports Med (1989) 1.25
Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood (1996) 1.23
Interactions between proteins and lipids from human red cell membranes. Chem Phys Lipids (1970) 1.19
The role of activated human platelets in prothrombin and factor X activation. Blood (1985) 1.19
Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1. J Clin Microbiol (2001) 1.18
Biomechanical analysis of sit-to-stand movement in normal and obese subjects. Clin Biomech (Bristol, Avon) (2003) 1.17
Prothrombin activation by an activator from the venom of Oxyuranus scutellatus (Taipan snake). J Biol Chem (1986) 1.17
Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother (2000) 1.17
Reproductive history and gastric cancer among post-menopausal women. Int J Cancer (1994) 1.16
Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther (2000) 1.16
Phospholipid scramblase activation pathways in lymphocytes. Biochemistry (2001) 1.15
Continuous analysis of the mechanism of activated transbilayer lipid movement in platelets. Biochemistry (1995) 1.15
Action of pure phospholipase A 2 and phospholipase C on human erythrocytes and ghosts. Biochim Biophys Acta (1971) 1.15
Membrane and lipid involvement in blood coagulation. Biochim Biophys Acta (1978) 1.14
Discovery of powerful gamma-ray flares from the Crab Nebula. Science (2011) 1.13
Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res (1995) 1.13
Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica (1997) 1.12
Exposure of endogenous phosphatidylserine at the outer surface of stimulated platelets is reversed by restoration of aminophospholipid translocase activity. Biochemistry (1989) 1.12
Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library. Eur J Biochem (1999) 1.11
Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure. Antivir Ther (1998) 1.10